Table 1.
Demographic data and clinical scores of patients with PD, AP and healthy controls
| PD T0 | PD T12 | AP‐SYN | AP‐TAU | HC | |
|---|---|---|---|---|---|
| Number and gender |
19 13 Male, 6 Female |
13 10 Male, 3 Female |
7 3 Male, 4 Female |
6 2 Male, 4 Female |
17 9 Male, 8 Female |
|
Median age (years) (quartiles) |
66 (56.5/73) |
67 (61/80) |
72 (66/73.5) |
76.5 * (71.5/77.8) |
57 (54/72) |
| Median disease duration (years) (quartiles) |
4.5 (3/7.8) |
6 (4/9) |
5.5 (2.8/7.5) |
4 (3.3/4.8) |
– |
|
Median H&Y Scale (quartiles) |
2 (1/3) |
2 (2/2) |
5 *** (3.5/5) |
4.5 *** (4/5) |
– |
| % Patients treated with L‐DOPA | 73.7% | 69% | – | – | – |
|
LEDD (mg) (quartiles) |
587.5 (337.5/762.5) |
495 (300/700) |
– | – | – |
| Median Beck Depression Scale (quartiles) |
6 (2.5/8.5) |
9 (4/12) |
8 (3.8/13) |
14 ** (11.8/15.5) |
– |
| Median MDS‐UPDRS (quartiles) | 22.50 (15.3/30.5) |
19 (13.5/26) |
– | – | – |
|
Median RBD (quartiles) |
3 (1.5/4) |
3 (2/5) |
3 (1.3/4.8) |
2.5 (0.3/4.8) |
– |
|
Median MMSE (quartiles) |
29 (28.5/30) |
30 (28/30) |
28 (26.3/29) |
24 ** (22/28) |
– |
|
Median MOCA (quartiles) |
27 (23.5/28.5) |
27 (20/28) |
24.5 (21.5/26) |
22 (16/23.5) |
– |
PD, control, and AP‐SYN groups did not differ in age, (Tukey post hoc test : |t 45| ≤ 2.02, P ≥ 0.19), while the APTAU subjects were significantly older than the healthy controls (Tukey post hoc test: t 45 = 2.85, P = 0.03). AP‐TAU and AP‐SYN had a more severe disease as measured by H&Y compared to PD subjects (P < 0.001). The sex ratio did not differ across patient groups (binomial GLM: χ2 3 = 3.01, P = 0.39). AP‐TAU subjects had significantly lower MMSE scores (Tukey post hoc test: t 27 = −3.74, P = 0.002) and significantly higher scores on the Beck Depression Inventory (Tukey post hoc test: t 28 = 3.23, P = 0.01) compared to PD group, while AP‐SYN subjects had intermediate values of both scores, not differing significantly from either the AP‐TAU group or the PD group (Tukey post hoc test: |t 27| ≤ 2.05, P ≥ 0.12). There was no significant difference in disease duration in the PD, AP‐SYN, and AP‐TAU groups (Poisson GLM: χ2 2 = 1.22, P = 0.54). *P < 0.05; **P < 0.01; ***P < 0.01.
PD, Parkinson Disease; AP, atypical parkinsonism; AP‐SYN, atypical parkinsonism with synucleinophaties; AP‐TAU, Atypical Parkinsonism with tauopathies; HC, healthy control; H&Y scale: Hoen and Yahr scale; LEDD, levodopa equivalent daily dose; MDS‐UPDRS, Movement Disorder Society ‐ Unified Parkinson's Disease Rating Scale; RBD, REM sleep behavior disorder screening questionnaire; MMSE, minimental state examination; MOCA, montreal cognitive assessment.